Elsevier

Vaccine

Volume 38, Issue 3, 16 January 2020, Pages 597-607
Vaccine

Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population

https://doi.org/10.1016/j.vaccine.2019.10.055Get rights and content

Highlights

  • Two novel modular approaches for assembly of lipopeptide-based vaccines developed.

  • These vaccines are self-adjuvanting and work in four different strains of mice.

  • Different chemical linkages and configurations of vaccine constructs investigated.

  • Stable bond between Pam2Cys and B cell epitope critical for antibody induction.

Abstract

To facilitate the preparation of synthetic epitope-based self-adjuvanting vaccines capable of eliciting antibody responses in an out-bred population, we have developed two modular approaches. In the first, the Toll-like receptor 2 agonist Pam2Cys and the target antibody epitope are assembled as a module which is then coupled to a carrier protein as a source of antigens to stimulate T cell help. A vaccine candidate made in this way was shown to induce a specific immune response in four different strains of mice without the need for extraneous adjuvant. In the second approach, three vaccine components in the form of a target antibody epitope, a T helper cell epitope and Pam2Cys, were prepared separately each carrying different chemical functional groups. By using pH-mediated chemo-selective ligations, the vaccine was assembled in a one-pot procedure. Using this approach, a number of vaccine constructs including a lipopeptide-protein conjugate were made and also shown to elicit immune responses in different strains of mice. These two modular approaches thus constitute a powerful platform for the assembly of self-adjuvanting lipopeptide-based vaccines that can potentially be used to induce robust antibody responses in an outbred population. Finally, our study of the impact of chemical linkages on immunogenicity of a lipopeptide vaccine shows that a stable covalent bond between Pam2Cys and a B cell epitope, rather than between Pam2Cys and T helper cell epitope is critical for the induction of antibody responses and biological efficacy, indicating that Pam2Cys functions not only as an adjuvant but also participates in processing and presentation of the immunogen.

Introduction

Recent years have seen efforts directed to the development of subunit vaccines for diseases where the use of attenuated or inactivated pathogens are not appropriate due to the potential risk of reversion to virulence, the presence of deleterious sequences or the limited availability of the antigens [1], [2]. One such strategy is to use peptide-based vaccine constructs containing target epitopes representing the minimal immunogenic region of an antigen allowing for precise direction of induced immune responses [1], [2]. Both free [3] and lipidated short peptides [4] were used successfully to raise virus-specific cytotoxic T lymphocyte responses by in vivo priming 30 years ago shortly after the first studies of peptide vaccine use in humans to treat cancer were reported [5]. Since then numerous studies of peptide-based vaccines have been carried out and have been reviewed [6], [7], [8], [9]. ClinicalTrials.gov, a website maintained by the National Institutes of Health lists 603 peptide vaccine-related clinical studies (October 2019) with 17 reaching Phase 3/4. Because of their relative small size, peptides lend themselves conveniently to chemical modification such as the attachment of carbohydrate antigens, lipid moieties and other functional groups leading us and others to develop the use of synthetic lipopeptides as self-adjuvanting vaccines [10]. Candidate lipopeptide vaccines that have been used in our studies typically comprise of the following three components: (i) a target epitope which can recognised by B or CD8+ T cells; (ii) a CD4+ T helper cell epitope (TH) to harness T helper cell-mediated responses important for initiating and maintaining immune responses to the target epitope and (iii) the lipid moiety S-[2,3-bis(palmitoyloxy)propyl]cysteine (Pam2Cys, or P2C in the figures), an agonist for Toll-like receptor-2 (TLR2) as a built-in adjuvant. Engagement of these lipopeptides by TLR2 on the dendritic cells results in their maturation, improved antigen uptake and processing leading to the induction of effective immune responses [11]. We have demonstrated that such lipopeptides, depending on the target epitope, are capable of inducing both humoral and cellular immunity in animals [10], [12], [13], [14], [15], [16], [17] and even mucosal responses if administered intranasally [10], [18].

Conventionally, these constructs are assembled in toto whereby the defined target and TH epitopes are synthesized contiguously but separated by an intervening lysine residue before attachment of Pam2Cys to its ε-amino group [10]. More recently, we have established a modular approach in which a TH epitope and Pam2Cys are first assembled as a module, which can then be coupled to a separately prepared target epitope [19] (Fig. 1A). This “TH modular approach”, enables the attachment of a conformational target epitope sequence i.e. a B cell epitope, that would otherwise be unlikely to fold correctly when assembled as a contiguous sequence. We have used this approach to build a candidate vaccine based on the heat-stable enterotoxin (ST) from enterotoxigenic Escherichia coli, which contains three-disulphide bridges in its tertiary structure. Antibodies to the ST-antigen elicited by this construct cross-react and neutralise the native toxin [19], [20].

In this study, we describe two novel approaches that extend this modular concept of assembling lipopeptide-based vaccines. The first approach is termed a “target modular approach” whereby the target epitope and Pam2Cys is now assembled as a module which can be coupled to a separately prepared TH epitope in a form as single peptide or a carrier protein (Fig. 1B). The TH epitope we have used here is a peptide determinant derived from the light chain of hemagglutinin of influenza virus (TFLU) that is recognised by CD4+ T cells in BALB/c mice [21]. Alternatively, a carrier protein was used to provide the source of TH epitopes overcoming the need to identify and use epitopes that are specific to an individual’s MHC Class II haplotype thereby potentially allowing this approach to be used in the outbred population. Here, we have used diphtheria tetanus toxoid (DT) which is not only a vaccine in itself [22] but also utilised as a protein carrier for carbohydrate- and peptide-conjugate human [23] and veterinary vaccines [24]. The target epitope is luteinizing hormone-releasing hormone (LHRH), a peptide hormone secreted by the hypothalamus to initiate a cascade of endocrine events that regulate reproduction in mammals. The sequence of this hormone is relatively conserved in all mammals and there are a multitude of studies which have shown that antibodies elicited against this hormone can effectively inhibit the reproductive capability of male and female mammals [10], [19].

The second approach is termed a “sequential ligation modular approach” and describes a potentially more flexible strategy in which each of the three components of a self-adjuvanting peptide vaccine are separately prepared before being assembled in a one-pot procedure. Both the TH epitope/carrier protein and the target epitope each carry a functional group that is chemically orthogonal to each other but complimentary to one of two functional groups that are incorporated into Pam2Cys (Fig. 1C). pH-mediated sequential chemoselective ligations of the lipid module with the target epitope followed by the TH epitope/carrier protein would then lead to the formation of the final vaccine construct.

Herein, we present the strategies used in the assembly of these constructs using these two approaches. We describe results of structural-functional experiments which allowed us to optimize the chemical linkages and positions of components as well as the progress of chemical reactions monitoring the progress of assembling these constructs. The ability of these constructs to induce antigen specific antibody responses without extraneous adjuvants were then evaluated in four different strains of mice including both conventional laboratory and humanised transgenic mouse strains to demonstrate the potential utility of this approach in the preparation of vaccines for use in an outbred population.

Section snippets

The general procedures of solid phase synthesis, cleavage, purification and mass analysis of peptides and lipopeptides

The synthesis of the target epitope LHRH (LHRH1-10; HWSYGLRPG), the influenza virus hemagglutinin derived IAb-restricted TH epitope TFLU (HA166-180; ALNNRFQIKGVELKS) and the ovalbumin derived IAd-restricted TH epitope TOVA (OVA329-339-; ISQAVHAAHAEINEAGR) were performed using Fmoc/tert-butyl strategy on a TentaGel S Ram resin (Rapp Polymere, Tuebingen, Germany) in a microwave-assisted peptide synthesizer (CEM, Liberty peptide synthesizer, Matthews, NC). Couplings were carried out using 5-fold

Evaluation of different chemical linkages and configurations for the assembly of LHRH-lipopeptide based vaccines using the target modular approach

To assemble a module comprised of the target epitope and Pam2Cys that is suitable to be conjugated to a single peptide or a carrier protein, a lysine residue was introduced to the N-terminus of LHRH to which Pam2Cys was coupled to its side chain following two serine residues as spacers. A thiol functional group was then introduced in the lipidated target epitope by coupling a cysteine to its N-terminus to form the lipidated target epitope module Cys-P2C-LHRH (1, Fig. 2). This module adapts a

Discussion

Conjugate vaccines currently licensed for human and veterinary use such as those against Haemophilus influenzae type B [38], various serotypes of Meningococcal and Pneumococcal species [39] and LHRH [24] comprise of a target antigen in the form of either carbohydrate or peptide conjugated to a carrier protein. The efficacy of these vaccines in an outbred population relies on the carrier protein to provide a source of epitopes that can be presented by different MHC class II haplotypes to

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This work was supported by Program Grant 567122 from the National Health and Medical Research Council of Australia.

References (53)

  • M. Thaysen-Andersen et al.

    Investigation of the detoxification mechanism of formaldehyde-treated tetanus toxin

    Vaccine

    (2007)
  • J.Z. Oh et al.

    TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway

    Blood

    (2011)
  • W. Zeng et al.

    Lipidation of intact proteins produces highly immunogenic vaccine candidates

    Mol Immunol

    (2011)
  • J. Alexander et al.

    Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides

    Immunity

    (1994)
  • T.M. Fu et al.

    Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys

    Vaccine

    (2009)
  • K. Rose et al.

    A synthetic peptide-based polyoxime vaccine construct of high purity and activity

    Mol Immunol

    (1995)
  • L.E. Brown et al.

    Lipid-based self-adjuvanting vaccines

    Curr Drug Deliv

    (2005)
  • A.W. Purcell et al.

    More than one reason to rethink the use of peptides in vaccine design

    Nat Rev Drug Discov

    (2007)
  • P. Aichele et al.

    Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide

    J Exp Med

    (1990)
  • K. Deres et al.

    In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

    Nature

    (1989)
  • R. He et al.

    Peptide conjugates with small molecules designed to enhance efficacy and safety

    Molecules

    (2019)
  • T. Kimura et al.

    Personalized peptide vaccines and their relation to other therapies in urological cancer

    Nat Rev Urol

    (2017)
  • W. Li et al.

    Peptide vaccine: progress and challenges

    Vaccines (Basel)

    (2014)
  • W. Zeng et al.

    Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines

    J Immunol

    (2002)
  • E.J. Mifsud et al.

    TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease

    Front Immunol

    (2014)
  • H.H. Alphs et al.

    Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2

    Proc Natl Acad Sci USA

    (2008)
  • Cited by (4)

    • The influence of component structural arrangement on peptide vaccine immunogenicity

      2022, Biotechnology Advances
      Citation Excerpt :

      This can be related to the replacement position of the fatty acids in the dihydroxypropyl moiety, in which the two 1,2-palmitoyl groups were vicinal within 58 conjugate, whereas the two 1,3-palmitoyl groups were separated by a carbon atom within 57 compound. The influence of different chemical linkages on the activity of Pam2Cys-based GnRH vaccine was further evaluated in four constructs (60–63) bearing influenza hemagglutinin-derived TFLU as the Th epitope (Fig. 14a) (Zeng et al., 2020). Compounds 60–62 were produced by chemoselective ligation via thioether bond formation.

    View full text